These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21155760)

  • 21. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
    Buser AS; Heim D; Bucher C; Tichelli A; Gratwohl A; Passweg JR
    Bone Marrow Transplant; 2004 May; 33(10):1011-4. PubMed ID: 15064693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
    Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
    Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
    Kyriakou C; Canals C; Finke J; Kobbe G; Harousseau JL; Kolb HJ; Novitzky N; Goldstone AH; Sureda A; Schmitz N
    J Clin Oncol; 2009 Aug; 27(24):3951-8. PubMed ID: 19620487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.
    Peggs KS; Kayani I; Edwards N; Kottaridis P; Goldstone AH; Linch DC; Hough R; Morris EC; Fielding A; Chakraverty R; Thomson KJ; Mackinnon S
    J Clin Oncol; 2011 Mar; 29(8):971-8. PubMed ID: 21282545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand?
    Anderlini P; Champlin RE
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):599-602. PubMed ID: 16737932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.
    Laurence AD; Goldstone AH
    Semin Hematol; 1999 Jul; 36(3):303-12. PubMed ID: 10462330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
    Patil S; Spencer A; Schwarer A; Lewis I; Hertzberg M; Avery S; Wei A; Noutsos T; Paul E; Taouk Y; Muirhead J
    Bone Marrow Transplant; 2010 Jul; 45(7):1154-60. PubMed ID: 19898502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
    Shimoni A; Hardan I; Ayuk F; Schilling G; Atanackovic D; Zeller W; Yerushalmi R; Zander AR; Kroger N; Nagler A
    Cancer; 2010 Aug; 116(15):3621-30. PubMed ID: 20564132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.
    Satwani P; Cooper N; Rao K; Veys P; Amrolia P
    Bone Marrow Transplant; 2008 Jan; 41(2):173-82. PubMed ID: 18037944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
    Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
    Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Avivi I; Montoto S; Canals C; Maertens J; Al-Ali H; Mufti GJ; Finke J; Schattenberg A; Fanin R; Cornelissen JJ; Vernant JP; Russell N; Beguin Y; Thomson K; Verdonck LF; Kobbe G; Tilly H; Socié G; Sureda A;
    Br J Haematol; 2009 Dec; 147(5):719-28. PubMed ID: 19793383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma.
    Paillard C; Salmon A; Curtillet C; David A; Halle P; Cachin F; Bordigoni P; Michel G; Rousseau R; Dore E; Isfan F; Merlin E; Rochette E; Demeocq F; Kanold J
    Pediatr Transplant; 2010 Feb; 14(1):109-14. PubMed ID: 19490483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
    Anderlini P; Saliba R; Acholonu S; Okoroji GJ; Donato M; Giralt S; Andersson B; Ueno NT; Khouri I; De Lima M; Hosing C; Cohen A; Ippoliti C; Romaguera J; Rodriguez MA; Pro B; Fayad L; Goy A; Younes A; Champlin RE
    Bone Marrow Transplant; 2005 May; 35(10):943-51. PubMed ID: 15806128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.
    Mohty M; Fegueux N; Exbrayat C; Lu ZY; Legouffe E; Quittet P; Lopez-Martinez E; Latry P; Avinens O; Hertog C; Klein B; Eliaou JF; Rossi JF
    Bone Marrow Transplant; 2001 Aug; 28(4):335-9. PubMed ID: 11571504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
    Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
    Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.